Drug Database
SC

Scherersol delivery systems (Polysol / Quadrisol / Cosol)

✓ Approved

Cardinal Health, Inc. · 小分子 · 小分子

什么是 Scherersol delivery systems?

Scherersol delivery systems 是一种小分子,由Cardinal Health, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Polysol, Quadrisol, Cosol
公司Cardinal Health, Inc.
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

Scherersol delivery systems 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedJournal of drug targeting2026-11-19

Precision-by-design nanotherapeutics: integrating molecular modeling, systems biology, and targeted drug delivery for next-generation personalized medicine.

Li Yanhui Y, Pal Roy Samaresh S, Roy Kalyan K, Kumar Arun A et al.

Nanotherapeutics offer significant potential for targeted drug delivery, controlled release, and molecularly directed treatment, but their development remains challenged by biological heterogeneity, formulation complexity, reproducibility, scale-up, and limited translation from experimental to clinical settings. This review proposes Precision-by-Design (PbD) as an emerging conceptual framework that extends established Quality-by-Design (QbD) principles by incorporating patient- and disease-related biological information into nanotherapeutic development. The framework integrates systems biology, multi-omics data, molecular modelling, computational formulation analysis, and targeted drug-delivery engineering to support biologically informed development decisions. Molecular modelling is considered at both drug-target and drug-carrier levels, including molecular interactions, nanocarrier organisation, stability, biological interfaces, and release mechanisms. Systems biology approaches are discussed for biomarker identification and patient stratification, with potential implications for formulation attributes. A HER2-positive breast cancer example illustrates how molecular information could theoretically guide investigation of target selection and formulation variables, including ligand density, particle size, surface characteristics, drug loading, and release behaviour. Importantly, PbD is not an established clinical formulation methodology, and its proposed benefits require experimental, preclinical, and clinical validation. Future research should emphasise model validation, standardised characterisation, clinically relevant performance measures, regulatory integration, and prospective evaluation of PbD-guided nanotherapeutic development.

PMID 43053491
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Engineered Metal-Organic Frameworks Preserve Mitochondrial Bioenergetics at Micromolar Concentrations.

D'Amato Marco M, Meo Ivano Di ID, Colombo Maria Nicol MN, Santanatoglia Chiara C et al.

Metal-Organic Frameworks (MOFs) are emerging as versatile materials for bio-interfaces due to their structural tunability and ability to integrate with biological systems. Among them, the Zeolitic Imidazolate Framework ZIF-8 is widely investigated as a carrier for the delivery of therapeutic agents owing to its chemical stability, porous architecture, and biocompatibility. Extending these strategies to complex biological substrates is particularly relevant for therapeutic applications. In this context, mitochondria represent key targets, as they regulate cellular metabolism and their dysfunction underlies numerous mitochondrial diseases, thereby stimulating growing interest in mitochondrial transplantation as a potential therapeutic approach. Here, we investigate the one-pot, in-situ formation of ZIF-8 coatings on isolated mitochondria under physiological conditions using mild micromolar precursor concentrations to minimize mitochondrial perturbation during the self-assembly process. Structural characterization and bioenergetic analyses confirm the formation of MITO@ZIF-8 and the preservation of mitochondrial respiratory competence. Transplantation of MITO@ZIF-8 into Mouse Embryonic Fibroblasts (MEFs) increases cellular respiratory capacity without affecting cell viability, indicating that the coating is biocompatible and does not impair mitochondrial uptake. These results provide a safe platform for the further engineering of delivery systems aimed at enhancing internalization efficiency in mitochondrial transplantation therapeutics.

PMID 43053354
阅读全文 →
PubMedExpert opinion on drug delivery2026-11-19

Dissolving and hydrogel-based polymeric microneedles for bacterial keratitis: materials, therapeutic payloads, design-performance relationships, and future perspectives.

Peirovi Babak B, Amanzadi Bentolhoda B, Censi Roberta R, Aghamollaei Hossein H

Bacterial keratitis (BK) is a major cause of corneal visual impairment. Although topical antibiotics remain the mainstay of treatment, tear turnover, blinking, nasolacrimal drainage, and the corneal epithelial barrier limit drug residence and penetration. Polymeric microneedles, particularly dissolving and hydrogel-based systems, may enhance ocular residence of therapeutic agents and enable controlled or sustained drug release. This review summarizes corneal anatomy and ocular drug-delivery barriers, outlines the pathophysiology of bacterial keratitis, and evaluates microneedle platforms developed for ocular applications, with emphasis on dissolving and hydrogel-based polymeric systems for bacterial keratitis. A focused search of PubMed, Scopus, and ScienceDirect was undertaken, supplemented by a search of Google Scholar to identify additional relevant studies. Relevant studies were compared according to polymer composition, microneedle dimensions and density, penetration depth, dissolution or swelling, and release kinetics. Polymer design-property relationships, including the effects of concentration, molecular weight, crosslinking, biodegradability, and post-administration polymer fate, are also discussed. Polymeric microneedles offer a promising strategy for overcoming corneal delivery barriers, but clinical translation will depend on reproducible manufacturing, mechanical and ocular safety, sterilization and storage stability, user-friendly application, and robust clinical evidence demonstrating advantages over optimized topical therapies.

PMID 43053713
阅读全文 →
PubMedMethods in molecular biology (Clifton, N.J.)2026-11-19

The Transformative Role of Artificial Intelligence in Wearable Health Monitoring: Applications in Diagnosis, Therapy, and Rehabilitation.

Shen Xiangru X, Luo Xuefeng X, Sun Yinsong Y, Zhu Zhenglin Z et al.

This chapter explores the transformative impact of artificial intelligence (AI)-augmented wearable technology in dynamic health monitoring across diagnosis, treatment, and rehabilitation. Innovations include real-time cardiovascular disease detection, AI-driven continuous glucose monitoring for diabetes, and neurological disorder tracking using flexible electroencephalograph (EEG) sensors. Therapeutic advances feature smart drug-delivery patches responsive to biomarkers, remote intervention systems, and surgical tools like augmented reality (AR) navigation. Rehabilitation breakthroughs encompass wearables for motor recovery, cardiopulmonary optimization, and neurorehabilitation using brain-computer interfaces. Future progress hinges on multifunctional hardware, federated learning for privacy, explainable AI, and standardized regulations.

PMID 43052671
阅读全文 →
PubMedChemphyschem : a European journal of chemical physics and physical chemistry2026-11-19

Bilayer Composition Controls Ferrocyanide Permeability in Soy Lecithin Vesicles.

Cañon J David Chamorro JDC, Luna M Alejandra MA, Correa N Mariano NM, Molina Patricia G PG

Soy lecithin vesicles are attractive nanocarriers owing to their biocompatibility, stability, and low cost. However, controlling the permeability of their bilayer remains a key challenge for their rational use in delivery systems. In this work, we demonstrate that the permeability of soy lecithin vesicles can be systematically tuned by modifying the bilayer composition through the incorporation of dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), and cholesterol. The resulting vesicular systems were characterized by dynamic light scattering (DLS), fluorescence spectroscopy using 6-propionyl-2-dimethylaminonaphthalene (PRODAN) as a probe of the bilayer microenvironment, and electrochemical measurements of potassium ferrocyanide (K4[Fe(CN)6]) release. Changes in lipid composition produced distinct PRODAN responses, consistent with differences in probe localization and bilayer organization, and markedly altered permeability toward encapsulated K4[Fe(CN)6]. The studied formulations spanned a broad range of K4[Fe(CN)6] release behaviors, from substantial retention to complete release at different rates. These results show that relatively small compositional changes provide a practical strategy for tuning the transport of this ionic probe across soy lecithin bilayers. Because permeability depends on the physicochemical nature of the encapsulated species, each prospective cargo must be evaluated in the selected formulation.

PMID 43052681
阅读全文 →
PubMedBMC nephrology2026-11-19

Recent advances in therapeutic signaling pathways in polycystic kidney disease: insights from contemporary translational disease models- a narrative review.

Kugita Masanori M, Yamaguchi Tamio T, Nagao Shizuko S

Polycystic kidney disease (PKD) has undergone a major conceptual reappraisal over the past decade. Although PKD is fundamentally a monogenic disorder caused by mutations in PKD1, PKD2, PKHD1, and related genes, it is now increasingly recognized that disease progression is regulated by complex and interconnected signaling networks arising from coordinated dysregulation across multiple regulatory pathways. Advances in experimental models, multi-omics technologies, and cross-species approaches have revealed that cyst initiation and progression arise from convergent defects in mechanosensation, epithelial proliferation, metabolic reprogramming, innate immune activation, and fibrotic remodeling. In this Review, we synthesize insights from genetically engineered mouse models, naturally occurring rodent strains, CRISPR/Cas9-based large-animal systems, and human cell-derived spheroids and induced pluripotent stem cell (iPSC)-derived kidney organoids. We highlight how conditional knockout platforms define the spatial and temporal origins of cystogenesis, whereas hypomorphic and allele-specific models clarify mutation- and dosage-dependent determinants of disease severity. These complementary systems connect upstream polycystin dysfunction to downstream therapeutic hubs, including vasopressin-cyclic AMP signaling, mTOR and AMPK pathways, Hippo-YAP/TAZ mechanotransduction, the cGAS-STING inflammatory axis, microRNA regulatory networks, and the gut-kidney axis. We further discuss how pathway-informed testing across model systems has accelerated the development of mechanism-based interventions, including vasopressin V2 receptor antagonists, nucleic acid-based microRNA therapeutics, metabolic modulators, kidney-targeted drug-delivery strategies, and rational combination therapies. Finally, we outline emerging directions for network-informed and stage-specific treatment strategies, emphasizing lineage-resolved targeting and translational validation in large-animal and human-derived platforms. This integrated framework provides a foundation for future therapies aimed at modifying the natural history of PKD.Clinical trial number Not applicable.

PMID 43052845
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多Scherersol delivery systems